The prognostic value of POD24 in relapsed/refractory follicular lymphoma – A SCHOLAR-5 analysis

‘Don’t keep me waiting’: estimating the impact on lifetime survival and QALYs of reduced vein-to-vein time for LBCL patients treated with CAR T in the 3L+ setting

Matching-Adjusted Indirect Comparisons of Axi-cel to Mosunetuzumab for the Treatment of Relapsed/Refractory Follicular Lymphoma

Single cell analysis reveals immune dysfunction in Large B cell Lymphoma (LBCL) pts with hypomagnesemia receiving Axi-cel: results from ZUMA-1 trial and Mayo Clinic cohort

Primary Overall Survival Analysis of the Phase 3 Randomized ZUMA-7 Study of Axicabtagene Ciloleucel Versus Standard of Care in Relapsed/Refractory Large B-Cell Lymphoma

ZUMA-23: A Global, Phase 3, Randomized Controlled Study of Axicabtagene Ciloleucel VersusStandard-of-Care as First-Line Therapy in Patients With High-Risk Large B-Cell Lymphoma